NASDAQ:JAZZ - Jazz Pharmaceuticals Stock Price, Price Target & More

$157.95 -0.77 (-0.49 %)
(As of 04/22/2018 04:00 PM ET)
Previous Close$157.95
Today's Range$156.69 - $159.01
52-Week Range$128.58 - $163.75
Volume259,664 shs
Average Volume413,298 shs
Market Capitalization$9.45 billion
P/E Ratio16.52
Dividend YieldN/A
Beta0.97

About Jazz Pharmaceuticals (NASDAQ:JAZZ)

Jazz Pharmaceuticals logoJazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops Solriamfetol (JZP-110), which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as in phase II clinical trial for ES associated with Parkinson's disease; Vyxeos for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy. In addition, it evaluates deuterated oxybate for narcolepsy; and sells psychiatry and other products. The company is headquartered in Dublin, Ireland.

Receive JAZZ News and Ratings via Email

Sign-up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:JAZZ
CUSIPG5087110
Phone353-1634-7800

Debt

Debt-to-Equity Ratio0.57%
Current Ratio3.29%
Quick Ratio3.15%

Price-To-Earnings

Trailing P/E Ratio16.52
Forward P/E Ratio13.76
P/E Growth0.83

Sales & Book Value

Annual Sales$1.62 billion
Price / Sales5.84
Cash Flow$13.0214 per share
Price / Cash12.13
Book Value$45.26 per share
Price / Book3.49

Profitability

EPS (Most Recent Fiscal Year)$9.56
Net Income$487.84 million
Net Margins30.14%
Return on Equity22.63%
Return on Assets10.74%

Miscellaneous

Employees1,210
Outstanding Shares59,800,000

How to Become a New Pot Stock Millionaire

Jazz Pharmaceuticals (NASDAQ:JAZZ) Frequently Asked Questions

What is Jazz Pharmaceuticals' stock symbol?

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals (NASDAQ:JAZZ) posted its quarterly earnings results on Tuesday, February, 27th. The specialty pharmaceutical company reported $2.58 EPS for the quarter, missing the consensus estimate of $2.73 by $0.15. The specialty pharmaceutical company earned $436.40 million during the quarter, compared to the consensus estimate of $440.91 million. Jazz Pharmaceuticals had a net margin of 30.14% and a return on equity of 22.63%. View Jazz Pharmaceuticals' Earnings History.

When is Jazz Pharmaceuticals' next earnings date?

Jazz Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Jazz Pharmaceuticals.

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals issued an update on its FY18 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of $12.65-13.25 for the period, compared to the Thomson Reuters consensus EPS estimate of $13.00. The company issued revenue guidance of $1.86-1.93 billion, compared to the consensus revenue estimate of $1.85 billion.

What price target have analysts set for JAZZ?

21 brokerages have issued 1 year target prices for Jazz Pharmaceuticals' shares. Their predictions range from $150.00 to $206.00. On average, they anticipate Jazz Pharmaceuticals' stock price to reach $181.8452 in the next twelve months. View Analyst Ratings for Jazz Pharmaceuticals.

What are Wall Street analysts saying about Jazz Pharmaceuticals stock?

Here are some recent quotes from research analysts about Jazz Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Jazz lowered its earnings guidance for 2017, mainly due to lower-than-expected sales from Xyrem. Xyrem is facing patent challenges in the United States. Jazz has also been facing difficulties in building sufficient inventory levels for leukemia drug, Erwinaze, due to constrained manufacturing capacity. The company has its share of pipeline setback too. However, its lead pipeline candidate, JZP-110, currently evaluated for treatment of EDS, complements its existing sleep disorder portfolio. Nonetheless, the FDA approval of, Vyxeos in August, lends huge boost to the company, given its huge commercial potential in the target market. Shares of the company outperformed the industry in the last one year." (1/12/2018)
  • 2. Cantor Fitzgerald analysts commented, "Cantor Fitzgerald will host a physician conference call on Tuesday to provide perspective on pitolisant as it relates to JAZZ’s sleep franchise. The call is at 1:00pm EST and the dial in number can be obtained from your Cantor sales rep. Note that the call will be 30 minutes in duration. Questions for the consultant can be emailed to [email protected]" (12/3/2017)

Who are some of Jazz Pharmaceuticals' key competitors?

Who are Jazz Pharmaceuticals' key executives?

Jazz Pharmaceuticals' management team includes the folowing people:
  • Mr. Bruce C. Cozadd, Co-Founder, Exec. Chairman & CEO (Age 54)
  • Mr. Matthew P. Young, Exec. VP & CFO (Age 49)
  • Ms. Suzanne Sawochka Hooper, Exec. VP & Gen. Counsel (Age 52)
  • Dr. Karen L. Smith, Chief Medical Officer and Exec. VP of R&D (Age 50)
  • Mr. Daniel N. Swisher Jr., Pres & COO (Age 55)

Has Jazz Pharmaceuticals been receiving favorable news coverage?

News coverage about JAZZ stock has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Jazz Pharmaceuticals earned a news impact score of 0.11 on Accern's scale. They also gave news articles about the specialty pharmaceutical company an impact score of 46.18 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Jazz Pharmaceuticals' stock price today?

One share of JAZZ stock can currently be purchased for approximately $157.95.

How big of a company is Jazz Pharmaceuticals?

Jazz Pharmaceuticals has a market capitalization of $9.45 billion and generates $1.62 billion in revenue each year. The specialty pharmaceutical company earns $487.84 million in net income (profit) each year or $9.56 on an earnings per share basis. Jazz Pharmaceuticals employs 1,210 workers across the globe.

How can I contact Jazz Pharmaceuticals?

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The specialty pharmaceutical company can be reached via phone at 353-1634-7800 or via email at [email protected]


MarketBeat Community Rating for Jazz Pharmaceuticals (JAZZ)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  755 (Vote Outperform)
Underperform Votes:  257 (Vote Underperform)
Total Votes:  1,012
MarketBeat's community ratings are surveys of what our community members think about Jazz Pharmaceuticals and other stocks. Vote "Outperform" if you believe JAZZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JAZZ will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
21 Wall Street analysts have issued ratings and price targets for Jazz Pharmaceuticals in the last 12 months. Their average twelve-month price target is $181.8452, suggesting that the stock has a possible upside of 15.13%. The high price target for JAZZ is $206.00 and the low price target for JAZZ is $150.00. There are currently 4 hold ratings and 17 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.812.802.762.77
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $181.8452$182.1875$180.3810$181.9091
Price Target Upside: 15.13% upside20.91% upside20.10% upside29.79% upside

Jazz Pharmaceuticals (NASDAQ:JAZZ) Consensus Price Target History

Price Target History for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Jazz Pharmaceuticals (NASDAQ:JAZZ) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/6/2018Seaport Global SecuritiesSet Price TargetBuy$175.00LowView Rating Details
3/23/2018HC WainwrightReiterated RatingNeutral$150.00 -> $160.00MediumView Rating Details
3/19/2018Morgan StanleyUpgradeEqual Weight -> Overweight$128.58 -> $163.75HighView Rating Details
3/1/2018Piper JaffrayReiterated RatingBuy$201.00LowView Rating Details
2/28/2018BMO Capital MarketsBoost Price TargetOutperform -> Outperform$196.00 -> $199.00HighView Rating Details
2/20/2018Bank of AmericaBoost Price TargetBuy -> Buy$164.00 -> $170.00LowView Rating Details
1/16/2018B. RileyReiterated RatingBuy$206.00LowView Rating Details
1/16/2018Deutsche BankSet Price TargetBuy$170.00MediumView Rating Details
1/2/2018Leerink SwannInitiated CoverageOutperform -> Outperform$180.00LowView Rating Details
12/25/2017Wells FargoReiterated RatingBuyLowView Rating Details
12/10/2017Cantor FitzgeraldReiterated RatingBuy$200.00LowView Rating Details
12/5/2017MizuhoBoost Price TargetNeutral -> Neutral$144.00 -> $150.00LowView Rating Details
11/8/2017UBSLower Price TargetBuy$172.00 -> $168.00N/AView Rating Details
11/8/2017Royal Bank of CanadaLower Price TargetOutperform$210.00 -> $195.00N/AView Rating Details
10/26/2017Stifel NicolausReiterated RatingBuy$190.00N/AView Rating Details
10/23/2017CowenSet Price TargetBuy$190.00N/AView Rating Details
10/19/2017FBR & CoInitiated CoverageBuy -> Buy$206.00N/AView Rating Details
9/28/2017Goldman SachsInitiated CoverageNeutral -> Neutral$165.00LowView Rating Details
9/18/2017JPMorgan ChaseReiterated RatingBuy$190.00LowView Rating Details
8/9/2017Janney Montgomery ScottReiterated RatingBuy$180.00 -> $192.00LowView Rating Details
5/22/2017Sanford C. BernsteinSet Price TargetMarket Perform$160.00 -> $176.00LowView Rating Details
2/22/2017Evercore ISIInitiated CoverageBuy$160.00N/AView Rating Details
2/16/2017GuggenheimReiterated RatingBuyN/AView Rating Details
1/19/2017SunTrust BanksReiterated RatingBuy$210.00N/AView Rating Details
1/18/2017BarclaysReiterated RatingOverweight$200.00N/AView Rating Details
(Data available from 4/22/2016 forward)

Earnings

Jazz Pharmaceuticals (NASDAQ:JAZZ) Earnings History and Estimates Chart

Earnings by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Jazz Pharmaceuticals (NASDAQ:JAZZ) Earnings Estimates

Current Year EPS Consensus Estimate: $11.48 EPS
Next Year EPS Consensus Estimate: $13.94 EPS

Jazz Pharmaceuticals (NASDAQ JAZZ) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018$2.76N/AView Earnings Details
2/27/2018Q4 2017$2.73$2.58$440.91 million$436.40 millionViewN/AView Earnings Details
11/7/2017Q3 2017$2.53$2.93$420.67 million$411.86 millionViewN/AView Earnings Details
8/8/20176/30/2017$1.85$1.72$410.83 million$394.39 millionViewListenView Earnings Details
5/9/20173/31/2017$1.42$1.41$376.58 million$376.10 millionViewListenView Earnings Details
2/28/2017Q416$2.65$1.91$398.91 million$396.62 millionViewListenView Earnings Details
11/8/2016Q316$2.61$2.16$389.34 million$374.00 millionViewListenView Earnings Details
8/9/2016Q216$2.80$2.63$376.40 million$381.00 millionViewN/AView Earnings Details
5/10/2016Q1$2.31$2.26$338.86 million$336.00 millionViewListenView Earnings Details
2/23/2016Q415$2.60$2.60$349.98 million$340.90 millionViewListenView Earnings Details
11/9/2015Q315$2.56$2.52$348.15 million$340.90 millionViewListenView Earnings Details
8/5/2015Q215$2.41$2.41$335.58 million$333.70 millionViewListenView Earnings Details
5/7/2015Q115$2.15$1.99$309.50 million$309.30 millionViewListenView Earnings Details
2/24/2015Q414$2.30$2.44$319.74 million$328.10 millionViewListenView Earnings Details
11/4/2014Q314$1.98$2.33$302.90 million$306.58 millionViewListenView Earnings Details
8/5/2014Q214$1.92$2.05$273.39 million$291.23 millionViewListenView Earnings Details
5/8/2014Q114$1.79$1.61$254.86 million$247.00 millionViewListenView Earnings Details
2/25/2014Q413$1.78$1.72$238.12 million$235.80 millionViewListenView Earnings Details
11/5/2013Q313$1.67$1.78$227.38 million$232.20 millionViewListenView Earnings Details
8/6/2013Q2 2013$1.52$1.43$208.71 million$208.30 millionViewListenView Earnings Details
5/7/2013Q1 2013$1.35$1.37$189.92 million$196.20 millionViewListenView Earnings Details
2/26/2013Q4 2012$1.41$1.53$183.80 million$183.70 millionViewListenView Earnings Details
11/8/2012Q312$1.31$1.29$178.57 million$175.50 millionViewN/AView Earnings Details
8/7/2012$1.05$1.09ViewN/AView Earnings Details
5/8/2012$0.90$0.91ViewN/AView Earnings Details
2/27/2012Q4 2011$1.01$0.96ViewN/AView Earnings Details
11/1/2011$0.89$0.94ViewN/AView Earnings Details
7/28/2011$0.67$0.82ViewN/AView Earnings Details
5/3/2011$0.57$0.59ViewN/AView Earnings Details
3/7/2011$0.60$0.63ViewN/AView Earnings Details
11/4/2010Q3 2010$0.29$0.32ViewN/AView Earnings Details
8/10/2010Q2 2010$0.14$0.17ViewN/AView Earnings Details
5/5/2010Q1 2010$0.14$0.12ViewN/AView Earnings Details
3/3/2010Q4 2009$0.05$0.17ViewN/AView Earnings Details
11/5/2009Q3 2009($0.14)($0.05)ViewN/AView Earnings Details
8/11/2009Q2 2009($0.33)$0.08ViewN/AView Earnings Details
5/7/2009Q1 2009($0.45)ViewN/AView Earnings Details
3/26/2009Q4 2008($1.08)($0.97)ViewN/AView Earnings Details
11/13/2008Q3 2008($1.25)($1.07)ViewN/AView Earnings Details
8/7/2008Q2 2008($1.74)($2.18)ViewN/AView Earnings Details
5/13/2008Q1 2008($1.65)($1.97)ViewN/AView Earnings Details
2/13/2008Q4 2007($1.87)($1.64)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Jazz Pharmaceuticals (NASDAQ:JAZZ) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Jazz Pharmaceuticals (NASDAQ JAZZ) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.30%
Institutional Ownership Percentage: 91.21%
Insider Trading History for Jazz Pharmaceuticals (NASDAQ:JAZZ)
Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Jazz Pharmaceuticals (NASDAQ JAZZ) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/16/2018Matthew P YoungCFOSell700$156.01$109,207.0038,465View SEC Filing  
4/13/2018Michael Patrick MillerEVPSell200$157.49$31,498.0027,481View SEC Filing  
4/10/2018Karen J WilsonSVPSell3,899$155.00$604,345.0019,517View SEC Filing  
4/2/2018Bruce C CozaddCEOSell1,000$150.01$150,010.00293,542View SEC Filing  
3/15/2018Matthew P YoungCFOSell700$151.22$105,854.0039,165View SEC Filing  
3/14/2018Michael Patrick MillerEVPSell200$151.12$30,224.0027,681View SEC Filing  
3/9/2018Bruce C CozaddCEOSell1,000$150.00$150,000.00294,542View SEC Filing  
3/6/2018Matthew P YoungCFOSell1,152$142.36$163,998.72View SEC Filing  
3/6/2018Paul TreacySVPSell594$141.47$84,033.18View SEC Filing  
3/2/2018Paul TreacySVPSell877$139.62$122,446.74View SEC Filing  
2/28/2018Bruce C CozaddCEOSell1,000$150.00$150,000.00267,468View SEC Filing  
2/28/2018Matthew P YoungCFOSell3,135$146.85$460,374.75View SEC Filing  
2/14/2018Michael Patrick MillerEVPSell200$139.99$27,998.0021,469View SEC Filing  
1/16/2018Matthew P. YoungCFOSell700$152.16$106,512.00View SEC Filing  
1/12/2018Bruce C. CozaddCEOSell3,000$150.00$450,000.00View SEC Filing  
1/12/2018Michael Patrick MillerEVPSell200$148.65$29,730.0021,669View SEC Filing  
12/11/2017Michael Patrick MillerEVPSell200$139.15$27,830.00View SEC Filing  
12/11/2017Patrick G. EnrightDirectorSell9,000$139.73$1,257,570.00View SEC Filing  
11/17/2017Iain McgillSVPSell8,000$133.42$1,067,360.0028,383View SEC Filing  
11/17/2017Patrick G EnrightDirectorSell352$133.19$46,882.881,365View SEC Filing  
10/2/2017Bruce C CozaddCEOSell1,000$150.00$150,000.00View SEC Filing  
9/12/2017Bruce C. CozaddCEOSell1,000$153.52$153,520.00View SEC Filing  
8/25/2017Patrick G EnrightDirectorSell351$148.40$52,088.401,717View SEC Filing  
8/15/2017Michael Patrick MillerEVPSell200$144.38$28,876.0021,996View SEC Filing  
8/14/2017Paul TreacySVPSell1,304$143.32$186,889.28View SEC Filing  
8/11/2017Paul L BernsDirectorSell662$142.37$94,248.946,599View SEC Filing  
7/20/2017Suzanne Sawochka HooperEVPSell4,580$160.00$732,800.0032,322View SEC Filing  
7/17/2017Michael Patrick MillerEVPSell200$154.97$30,994.00View SEC Filing  
6/23/2017Suzanne Sawochka HooperEVPSell420$160.00$67,200.00View SEC Filing  
6/15/2017Michael Patrick MillerEVPSell200$150.65$30,130.0022,223View SEC Filing  
6/1/2017Rick E WinninghamDirectorSell5,000$150.00$750,000.0010,391View SEC Filing  
5/15/2017Michael Patrick MillerEVPSell200$152.98$30,596.0022,623View SEC Filing  
5/11/2017Bruce C CozaddCEOSell30,000$153.47$4,604,100.00296,418View SEC Filing  
5/9/2017Suzanne Sawochka HooperEVPSell2,500$160.00$400,000.0037,149View SEC Filing  
4/27/2017Karen J WilsonSVPSell1,275$160.00$204,000.0021,133View SEC Filing  
4/27/2017Suzanne Sawochka HooperEVPSell2,500$160.00$400,000.0039,649View SEC Filing  
4/17/2017Michael Patrick MillerSVPSell200$152.56$30,512.0022,562View SEC Filing  
4/11/2017Bruce C CozaddCEOSell1,000$152.12$152,120.00308,491View SEC Filing  
4/10/2017Karen J WilsonSVPSell11,458$152.24$1,744,365.9227,158View SEC Filing  
3/15/2017Michael Patrick MillerSVPSell200$137.89$27,578.0022,762View SEC Filing  
3/6/2017Paul TreacySVPSell884$131.97$116,661.4818,108View SEC Filing  
2/15/2017Michael Patrick MillerSVPSell200$134.55$26,910.0016,486View SEC Filing  
1/18/2017Russell J. CoxCOOSell4,000$128.75$515,000.00View SEC Filing  
1/17/2017Michael Patrick MillerSVPSell200$115.93$23,186.0016,686View SEC Filing  
12/15/2016Michael Patrick MillerSVPSell200$103.09$20,618.00View SEC Filing  
12/2/2016Patrick G EnrightDirectorSell677$101.80$68,918.601,365View SEC Filing  
11/15/2016Michael Patrick MillerSVPSell200$112.19$22,438.0016,925View SEC Filing  
11/14/2016Kenneth W O'keefeDirectorBuy2,000$113.84$227,680.0012,107View SEC Filing  
10/17/2016Michael Patrick MillerSVPSell200$118.16$23,632.0017,125View SEC Filing  
9/19/2016Michael Patrick MillerSVPSell200$126.17$25,234.0017,325View SEC Filing  
8/25/2016Seamus MulliganDirectorSell27,968$128.32$3,588,853.761,072,411View SEC Filing  
8/16/2016Paul TreacySVPSell1,292$137.47$177,611.24View SEC Filing  
8/15/2016Michael Patrick MillerSVPSell100$136.45$13,645.0017,525View SEC Filing  
8/15/2016Rick E WinninghamDirectorSell633$136.45$86,372.8515,391View SEC Filing  
8/12/2016Karen L SmithInsiderBuy608$137.10$83,356.8014,181View SEC Filing  
8/9/2016Bruce C. CozaddCEOSell1,000$150.00$150,000.00View SEC Filing  
8/9/2016Russell J. CoxCOOSell4,000$148.66$594,640.00View SEC Filing  
7/15/2016Michael Patrick MillerSVPSell100$142.43$14,243.0017,625View SEC Filing  
7/13/2016Karen L SmithCMOBuy580$143.63$83,305.4013,574View SEC Filing  
6/15/2016Michael Patrick MillerSVPSell100$149.64$14,964.0017,725View SEC Filing  
6/13/2016Karen L SmithCMOBuy557$149.61$83,332.7712,994View SEC Filing  
5/16/2016Heather Ann McsharryDirectorSell697$145.20$101,204.405,396View SEC Filing  
5/16/2016Michael Patrick MillerSVPSell100$145.20$14,520.0017,753View SEC Filing  
4/25/2016Karen J WilsonSVPSell604$160.00$96,640.0018,059View SEC Filing  
4/15/2016Michael Patrick MillerSVPSell100$145.79$14,579.0018,792View SEC Filing  
4/13/2016Karen J WilsonSVPSell5,007$150.00$751,050.0018,663View SEC Filing  
4/12/2016Russell J CoxCOOSell4,000$136.98$547,920.0060,470View SEC Filing  
4/7/2016Karen J WilsonSVPSell2,161$140.90$304,484.9023,670View SEC Filing  
3/15/2016Michael Patrick MillerSVPSell100$129.17$12,917.0018,892View SEC Filing  
3/8/2016Bruce C CozaddCEOSell2,500$126.04$315,100.00302,566View SEC Filing  
2/29/2016Paul TreacySVPSell354$123.48$43,711.9215,102View SEC Filing  
2/23/2016Seamus MulliganDirectorSell27,968$122.71$3,431,953.281,127,831View SEC Filing  
2/16/2016Michael Patrick MillerSVPSell100$115.63$11,563.0013,461View SEC Filing  
2/10/2016Patrick G EnrightDirectorSell10,000$117.92$1,179,200.001,310View SEC Filing  
2/9/2016Bruce C CozaddCEOSell2,500$111.37$278,425.00281,896View SEC Filing  
1/15/2016Michael Patrick MillerSVPSell100$122.66$12,266.0013,561View SEC Filing  
1/12/2016Bruce C CozaddCEOSell2,500$123.81$309,525.00284,396View SEC Filing  
1/5/2016Patrick G EnrightDirectorSell10,000$138.09$1,380,900.001,310View SEC Filing  
12/15/2015Michael Patrick MillerSVPSell100$136.99$13,699.0013,661View SEC Filing  
12/8/2015Bruce C CozaddCEOSell2,500$139.72$349,300.00286,855View SEC Filing  
12/2/2015Patrick G EnrightDirectorSell10,424$146.67$1,528,888.081,310View SEC Filing  
11/23/2015Seamus MulliganDirectorSell27,968$145.86$4,079,412.481,130,547View SEC Filing  
11/10/2015Bruce C CozaddCEOSell2,500$128.53$321,325.00289,355View SEC Filing  
11/10/2015Patrick G EnrightDirectorSell10,000$135.29$1,352,900.001,734View SEC Filing  
10/21/2015Suzanne Sawochka HooperEVPSell2,000$125.00$250,000.0035,855View SEC Filing  
10/13/2015Bruce C CozaddCEOSell2,500$131.50$328,750.00291,855View SEC Filing  
10/5/2015Patrick G EnrightDirectorSell10,000$133.79$1,337,900.001,734View SEC Filing  
9/25/2015Michael Patrick MillerSVPSell100$145.23$14,523.0013,890View SEC Filing  
9/8/2015Bruce C. CozaddCEOSell2,500$163.07$407,675.00294,355View SEC Filing  
9/1/2015Patrick G EnrightDirectorSell10,000$165.99$1,659,900.001,734View SEC Filing  
7/14/2015Bruce C CozaddCEOSell5,000$177.79$888,950.00View SEC Filing  
7/14/2015Suzanne Sawochka HooperEVPSell4,000$177.79$711,160.00View SEC Filing  
7/6/2015Patrick G EnrightDirectorSell10,000$177.11$1,771,100.00View SEC Filing  
6/9/2015Bruce C CozaddCEOSell5,000$173.16$865,800.00View SEC Filing  
6/9/2015Suzanne Sawochka HooperEVPSell4,000$173.16$692,640.00View SEC Filing  
6/2/2015Karen J WilsonSVPSell5,751$179.59$1,032,822.09View SEC Filing  
6/1/2015Karen J WilsonSVPSell5,494$179.57$986,557.58View SEC Filing  
4/14/2015Bruce C CozaddCEOSell5,000$181.45$907,250.00View SEC Filing  
4/14/2015Suzanne Sawochka HooperEVPSell4,000$181.45$725,800.00View SEC Filing  
3/25/2015Seamus MulliganDirectorSell50,000$174.59$8,729,500.00View SEC Filing  
1/5/2015Patrick G EnrightDirectorSell10,000$160.25$1,602,500.00View SEC Filing  
12/26/2014Seamus MulliganDirectorSell50,000$163.40$8,170,000.00View SEC Filing  
12/12/2014Patrick G EnrightDirectorSell2,343$170.98$400,606.14View SEC Filing  
12/9/2014Bruce C CozaddCEOSell5,000$178.79$893,950.00View SEC Filing  
12/9/2014Suzanne Sawochka HooperEVPSell1,852$178.79$331,119.08View SEC Filing  
12/1/2014Patrick G EnrightDirectorSell10,000$172.74$1,727,400.00View SEC Filing  
11/24/2014Jeffrey K TobiasCMOSell4,598$170.12$782,211.76View SEC Filing  
11/7/2014Iain McgillSVPSell7,066$172.03$1,215,563.98View SEC Filing  
10/10/2014Jeffrey K TobiasCMOSell1,000$154.04$154,040.00View SEC Filing  
10/6/2014Patrick G EnrightDirectorSell10,000$160.56$1,605,600.00View SEC Filing  
9/25/2014Seamus MulliganDirectorSell50,000$163.16$8,158,000.00View SEC Filing  
9/24/2014Seamus MulliganDirectorSell35,294$163.70$5,777,627.80View SEC Filing  
9/12/2014Jeffrey K TobiasCMOSell1,000$171.22$171,220.00View SEC Filing  
9/11/2014Karen J WilsonSVPSell3,000$175.00$525,000.00View SEC Filing  
9/11/2014Seamus MulliganDirectorSell50,000$175.00$8,750,000.00View SEC Filing  
9/9/2014Bruce C CozaddCEOSell5,000$170.32$851,600.00View SEC Filing  
9/8/2014Karen J WilsonSVPSell2,500$170.00$425,000.00View SEC Filing  
9/8/2014Suzanne Sawochka HooperEVPSell1,852$168.00$311,136.00View SEC Filing  
8/12/2014Bruce C CozaddCEOSell5,000$133.15$665,750.00View SEC Filing  
8/12/2014Suzanne Sawochka HooperEVPSell1,185$133.15$157,782.75View SEC Filing  
8/11/2014Jeffrey K TobiasCMOSell4,933$135.42$668,026.86View SEC Filing  
7/8/2014Bruce C CozaddCEOSell5,000$155.00$775,000.00View SEC Filing  
7/8/2014Suzanne Sawochka HooperEVPSell1,853$155.00$287,215.00View SEC Filing  
7/7/2014Karen J WilsonSVPSell2,500$165.00$412,500.00View SEC Filing  
6/25/2014Seamus MulliganDirectorSell50,000$149.69$7,484,500.00View SEC Filing  
6/20/2014Russell J CoxCOOSell2,000$155.00$310,000.00View SEC Filing  
6/17/2014Fintan KeeganEVPSell3,750$150.00$562,500.00View SEC Filing  
6/10/2014Bruce C CozaddCEOSell5,000$142.34$711,700.00View SEC Filing  
5/16/2014Jeffrey TobiasCMOSell1,000$128.01$128,010.0047,103View SEC Filing  
5/13/2014Bruce CozaddCEOSell5,000$128.92$644,600.00606,810View SEC Filing  
4/17/2014Rick WinninghamDirectorSell27,500$140.00$3,850,000.0013,587View SEC Filing  
4/14/2014Jeffrey TobiasCMOSell3,000$128.54$385,620.0048,103View SEC Filing  
4/8/2014Bruce CozaddCEOSell5,000$123.18$615,900.00611,810View SEC Filing  
3/10/2014Jeffrey TobiasCMOSell3,000$152.99$458,970.0048,103View SEC Filing  
3/6/2014Fintan KeeganEVPSell4,640$159.90$741,936.0039,272View SEC Filing  
3/4/2014Seamus MulliganDirectorSell550,000$156.25$85,937,500.001,455,555View SEC Filing  
3/3/2014Patrick EnrightDirectorSell559,628$152.39$85,281,710.92View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Jazz Pharmaceuticals (NASDAQ JAZZ) News Headlines

Source:
DateHeadline
Jazz Pharmaceuticals (JAZZ) Given a $210.00 Price Target by Royal Bank of Canada AnalystsJazz Pharmaceuticals (JAZZ) Given a $210.00 Price Target by Royal Bank of Canada Analysts
www.americanbankingnews.com - April 20 at 3:00 PM
Jazz Pharmaceuticals (JAZZ) Receives Consensus Recommendation of "Buy" from AnalystsJazz Pharmaceuticals (JAZZ) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 20 at 1:40 AM
Jazz Pharmaceuticals (JAZZ) CFO Matthew P. Young Sells 700 SharesJazz Pharmaceuticals (JAZZ) CFO Matthew P. Young Sells 700 Shares
www.americanbankingnews.com - April 18 at 7:46 PM
Jazz Pharmaceuticals (JAZZ) EVP Sells $31,498.00 in StockJazz Pharmaceuticals (JAZZ) EVP Sells $31,498.00 in Stock
www.americanbankingnews.com - April 13 at 7:27 PM
BidaskClub Lowers Jazz Pharmaceuticals (JAZZ) to SellBidaskClub Lowers Jazz Pharmaceuticals (JAZZ) to Sell
www.americanbankingnews.com - April 13 at 4:23 PM
Jazz Pharmaceuticals (JAZZ) Upgraded by BidaskClub to HoldJazz Pharmaceuticals (JAZZ) Upgraded by BidaskClub to Hold
www.americanbankingnews.com - April 13 at 10:02 AM
Jazz Pharmaceuticals (JAZZ) Lifted to Buy at Zacks Investment ResearchJazz Pharmaceuticals (JAZZ) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - April 12 at 7:25 PM
Jazz Pharmaceuticals (JAZZ) SVP Karen J. Wilson Sells 3,899 SharesJazz Pharmaceuticals (JAZZ) SVP Karen J. Wilson Sells 3,899 Shares
www.americanbankingnews.com - April 12 at 7:18 PM
Jazz Pharmaceuticals (JAZZ) Receives Buy Rating from Janney Montgomery ScottJazz Pharmaceuticals (JAZZ) Receives Buy Rating from Janney Montgomery Scott
www.americanbankingnews.com - April 12 at 2:19 PM
Jazz Pharmaceuticals (JAZZ) Stock Rating Reaffirmed by Royal Bank of CanadaJazz Pharmaceuticals (JAZZ) Stock Rating Reaffirmed by Royal Bank of Canada
www.americanbankingnews.com - April 12 at 12:33 PM
Jazz Pharmaceuticals (JAZZ) "Outperform" Rating Reiterated at CowenJazz Pharmaceuticals' (JAZZ) "Outperform" Rating Reiterated at Cowen
www.americanbankingnews.com - April 11 at 6:13 PM
Jazz Pharmaceuticals (JAZZ) Receives "Outperform" Rating from Wells FargoJazz Pharmaceuticals (JAZZ) Receives "Outperform" Rating from Wells Fargo
www.americanbankingnews.com - April 11 at 4:31 PM
Jazz Pharmaceuticals (JAZZ) Buy Rating Reiterated at Piper JaffrayJazz Pharmaceuticals' (JAZZ) Buy Rating Reiterated at Piper Jaffray
www.americanbankingnews.com - April 10 at 10:31 PM
$434.02 Million in Sales Expected for Jazz Pharmaceuticals (JAZZ) This Quarter$434.02 Million in Sales Expected for Jazz Pharmaceuticals (JAZZ) This Quarter
www.americanbankingnews.com - April 10 at 2:38 AM
 Analysts Expect Jazz Pharmaceuticals (JAZZ) to Post $2.73 EPS Analysts Expect Jazz Pharmaceuticals (JAZZ) to Post $2.73 EPS
www.americanbankingnews.com - April 8 at 5:20 PM
Jazz Pharmaceuticals (JAZZ) Given a $175.00 Price Target by Seaport Global Securities AnalystsJazz Pharmaceuticals (JAZZ) Given a $175.00 Price Target by Seaport Global Securities Analysts
www.americanbankingnews.com - April 6 at 2:28 PM
Insider Selling: Jazz Pharmaceuticals plc - (JAZZ) CEO Sells 1,000 Shares of StockInsider Selling: Jazz Pharmaceuticals plc - (JAZZ) CEO Sells 1,000 Shares of Stock
www.americanbankingnews.com - April 4 at 11:17 PM
Jazz Pharmaceuticals (JAZZ) Downgraded to Hold at Zacks Investment ResearchJazz Pharmaceuticals (JAZZ) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 2 at 7:30 PM
Royal Bank of Canada Lowers Jazz Pharmaceuticals (JAZZ) Price Target to $195.00Royal Bank of Canada Lowers Jazz Pharmaceuticals (JAZZ) Price Target to $195.00
www.americanbankingnews.com - April 1 at 11:24 AM
Royal Bank of Canada Reaffirms "Outperform" Rating for Jazz Pharmaceuticals (JAZZ)Royal Bank of Canada Reaffirms "Outperform" Rating for Jazz Pharmaceuticals (JAZZ)
www.americanbankingnews.com - April 1 at 11:24 AM
Jazz Pharmaceuticals (JAZZ) Given a $170.00 Price Target by Deutsche Bank AnalystsJazz Pharmaceuticals (JAZZ) Given a $170.00 Price Target by Deutsche Bank Analysts
www.americanbankingnews.com - March 28 at 2:07 PM
Jazz Pharmaceuticals (JAZZ) Earns "Buy" Rating from B. RileyJazz Pharmaceuticals (JAZZ) Earns "Buy" Rating from B. Riley
www.americanbankingnews.com - March 28 at 12:58 PM
Jazz Pharmaceuticals plc - (JAZZ) Receives Average Recommendation of "Buy" from AnalystsJazz Pharmaceuticals plc - (JAZZ) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 26 at 1:50 AM
Jazz Pharmaceuticals plc - (JAZZ) Expected to Post Quarterly Sales of $432.77 MillionJazz Pharmaceuticals plc - (JAZZ) Expected to Post Quarterly Sales of $432.77 Million
www.americanbankingnews.com - March 24 at 4:14 AM
HC Wainwright Reiterates Hold Rating for Jazz Pharmaceuticals (JAZZ)HC Wainwright Reiterates Hold Rating for Jazz Pharmaceuticals (JAZZ)
www.americanbankingnews.com - March 23 at 2:57 PM
$2.73 Earnings Per Share Expected for Jazz Pharmaceuticals plc - (JAZZ) This Quarter$2.73 Earnings Per Share Expected for Jazz Pharmaceuticals plc - (JAZZ) This Quarter
www.americanbankingnews.com - March 22 at 5:20 PM
Jazz Pharmaceuticals plc - (JAZZ) CFO Sells $105,854.00 in StockJazz Pharmaceuticals plc - (JAZZ) CFO Sells $105,854.00 in Stock
www.americanbankingnews.com - March 19 at 8:14 PM
Jazz Pharmaceuticals (JAZZ) Stock Rating Upgraded by Morgan StanleyJazz Pharmaceuticals (JAZZ) Stock Rating Upgraded by Morgan Stanley
www.americanbankingnews.com - March 19 at 6:12 PM
Jazz Pharmaceuticals (JAZZ) Upgraded by BidaskClub to "Sell"Jazz Pharmaceuticals (JAZZ) Upgraded by BidaskClub to "Sell"
www.americanbankingnews.com - March 18 at 6:06 PM
Jazz Pharmaceuticals plc - (JAZZ) EVP Michael Patrick Miller Sells 200 SharesJazz Pharmaceuticals plc - (JAZZ) EVP Michael Patrick Miller Sells 200 Shares
www.americanbankingnews.com - March 16 at 8:52 PM
Should Value Investors Pick Jazz Pharmaceuticals (JAZZ) Stock?Should Value Investors Pick Jazz Pharmaceuticals (JAZZ) Stock?
finance.yahoo.com - March 16 at 6:30 PM
Jazz Pharmaceuticals plc - (JAZZ) CEO Bruce C. Cozadd Sells 1,000 SharesJazz Pharmaceuticals plc - (JAZZ) CEO Bruce C. Cozadd Sells 1,000 Shares
www.americanbankingnews.com - March 13 at 8:17 PM
Jazz Pharmaceuticals (JAZZ) Shares Cross Above 200 DMA - Nasdaq - NasdaqJazz Pharmaceuticals (JAZZ) Shares Cross Above 200 DMA - Nasdaq - Nasdaq
www.nasdaq.com - March 9 at 8:19 AM
Jazz Pharmaceuticals plc - (JAZZ) SVP Sells $84,033.18 in StockJazz Pharmaceuticals plc - (JAZZ) SVP Sells $84,033.18 in Stock
www.americanbankingnews.com - March 7 at 7:30 PM
Jazz Pharmaceuticals plc - (JAZZ) CFO Matthew P. Young Sells 1,152 SharesJazz Pharmaceuticals plc - (JAZZ) CFO Matthew P. Young Sells 1,152 Shares
www.americanbankingnews.com - March 7 at 7:12 PM
Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in MarchJazz Pharmaceuticals Announces Participation in Two Investor Conferences in March
finance.yahoo.com - March 6 at 5:41 PM
BlackRock Inc. Has $378.66 Million Stake in Jazz Pharmaceuticals plc - (JAZZ)BlackRock Inc. Has $378.66 Million Stake in Jazz Pharmaceuticals plc - (JAZZ)
www.americanbankingnews.com - March 6 at 5:02 AM
Jazz Pharmaceuticals plc - (JAZZ) SVP Sells $122,446.74 in StockJazz Pharmaceuticals plc - (JAZZ) SVP Sells $122,446.74 in Stock
www.americanbankingnews.com - March 5 at 7:18 PM
Jazz Pharmaceuticals plc - (JAZZ) Expected to Announce Earnings of $2.73 Per ShareJazz Pharmaceuticals plc - (JAZZ) Expected to Announce Earnings of $2.73 Per Share
www.americanbankingnews.com - March 5 at 1:18 PM
OppenheimerFunds Inc. Reduces Position in Jazz Pharmaceuticals plc - (JAZZ)OppenheimerFunds Inc. Reduces Position in Jazz Pharmaceuticals plc - (JAZZ)
www.americanbankingnews.com - March 5 at 10:07 AM
Aviance Capital Partners LLC Has $2.17 Million Holdings in Jazz Pharmaceuticals plc - (JAZZ)Aviance Capital Partners LLC Has $2.17 Million Holdings in Jazz Pharmaceuticals plc - (JAZZ)
www.americanbankingnews.com - March 5 at 4:45 AM
Suntrust Banks Inc. Reduces Position in Jazz Pharmaceuticals plc - (JAZZ)Suntrust Banks Inc. Reduces Position in Jazz Pharmaceuticals plc - (JAZZ)
www.americanbankingnews.com - March 4 at 11:04 AM
Jazz Pharmaceuticals (JAZZ) Announces FDA Acceptance of NDA ... - StreetInsider.comJazz Pharmaceuticals (JAZZ) Announces FDA Acceptance of NDA ... - StreetInsider.com
www.streetinsider.com - March 4 at 8:15 AM
Jazz Pharmaceuticals plc - (JAZZ) Shares Bought by Maverick Capital Ltd.Jazz Pharmaceuticals plc - (JAZZ) Shares Bought by Maverick Capital Ltd.
www.americanbankingnews.com - March 4 at 8:02 AM
Jazz Pharmaceuticals (JAZZ) Announces FDA Acceptance of NDA for SolriamfetolJazz Pharmaceuticals (JAZZ) Announces FDA Acceptance of NDA for Solriamfetol
www.streetinsider.com - March 3 at 6:27 PM
Jazz Pharmaceuticals plc - (JAZZ) Shares Bought by UBS Asset Management Americas Inc.Jazz Pharmaceuticals plc - (JAZZ) Shares Bought by UBS Asset Management Americas Inc.
www.americanbankingnews.com - March 3 at 9:08 AM
Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness ... - PR Newswire (press release)Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness ... - PR Newswire (press release)
www.prnewswire.com - March 3 at 8:15 AM
State of Wisconsin Investment Board Sells 844 Shares of Jazz Pharmaceuticals plc - (JAZZ)State of Wisconsin Investment Board Sells 844 Shares of Jazz Pharmaceuticals plc - (JAZZ)
www.americanbankingnews.com - March 2 at 7:50 PM
BRIEF-Jazz Announces FDA Acceptance Of NDA For Solriamfetol For Excessive Sleepiness Associated With Narcolepsy Or Obstructive Sleep ApneaBRIEF-Jazz Announces FDA Acceptance Of NDA For Solriamfetol For Excessive Sleepiness Associated With Narcolepsy Or Obstructive Sleep Apnea
www.reuters.com - March 2 at 6:12 PM
Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep ApneaJazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
finance.yahoo.com - March 2 at 6:12 PM

SEC Filings

Jazz Pharmaceuticals (NASDAQ:JAZZ) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Jazz Pharmaceuticals (NASDAQ:JAZZ) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Jazz Pharmaceuticals (NASDAQ JAZZ) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.